IMR Press / FBS / Volume 4 / Issue 3 / DOI: 10.2741/S304

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy

Show Less
1 Department Of Pathology, College of Medicine King Saud University, Riyadh, 11461 Saudi Arabia
2 Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY 14214, USA
3 Department of Microbiology, and Immunology, University at Buffalo, Buffalo, NY 14214, USA
4 Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, 65212
5 Harry S. Truman Memorial Veterans Hospital, Columbia, MO 65201
6 Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263

*Author to whom correspondence should be addressed.

Academic Editor: Hafiz Ahmed

Front. Biosci. (Schol Ed) 2012, 4(3), 840–863;
Published: 1 January 2012
(This article belongs to the Special Issue Glycobiology of cancer)

Thomsen-Friedenreich antigen (TF-Ag) is the disaccharide (Gal beta1-3 GalNAc alpha), which is also known as the core 1 structure. The presence of this disaccharide on the surface of ~90% of carcinomas is due to altered glycosylation in these tumors. TF-Ag plays a role in the adhesive properties of tumor cells involved in metastasis. Treatment of mice with JAA-F11, a monoclonal antibody to TF-Ag alpha inhibited lung metastasis and improved prognosis in a mouse breast cancer model. The presence of naturally occurring antibodies to TF-Ag in cancer patients is related to improved prognosis. The pancarcinoma expression of TF-Ag, combined with the evidence of a mechanistic role for TF-Ag in cancer spread, show that this target would have clinical utility. The presence of naturally occurring antibody to TF-Ag indicates that increasing the anti-TF-Ag antibody would be safe for the cancer patient and indicates that tolerance would not have to be broken to create this immune response. Finally, the prognostic improvements seen clinically and in animal models indicate that this is an important vaccine target.

Back to top